Cerevel Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates

Rhea-AI Summary

Cerevel Therapeutics reported its Q2 2022 financial results and provided updates on its pipeline, emphasizing a commitment to neuroscience therapies. The company has initiated two Phase 2 trials for emraclidine in schizophrenia, with data expected in 1H 2024. Cerevel maintains a healthy cash position of $531M, projected to support operations through 2024. Additionally, the company is advancing its drug candidates, including darigabat for epilepsy and panic disorder, and tavapadon for Parkinson’s disease. The total R&D expenditure significantly rose to $72.5M for Q2.

Positive

• Initiated two Phase 2 trials for emraclidine in schizophrenia, with data expected in 1H 2024.
• Strong cash position of $531M expected to support operations into 2024.
• Ongoing development of multiple promising drug candidates across neuroscience indications.

Negative

• Research and development expenses increased significantly to $72.5M for Q2, raising concerns about cost management.
• General and administrative expenses also rose to $20.5M for Q2, indicating higher operational costs.

Initiated two parallel, adequately-powered Phase 2 trials of emraclidine in schizophrenia with data expected 1H 2024

Phase 1 trial of emraclidine to be initiated by year-end to support future development in Alzheimer’s disease psychosis

Panic disorder selected as second indication for darigabat, planning underway for Phase 2 proof-of-concept

Cash, cash equivalents and marketable securities of $531M as of June 30, 2022, expected to support operations into 2024

Conference call today at 8:00 a.m. ET

CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the quarter ended June 30, 2022 and provided key pipeline and business updates.

“At Cerevel, it is our aspiration to become the premier neuroscience company. We are well on our way to achieving this distinction with a broad and deep pipeline of potential new therapies and compelling early data in schizophrenia, which has led us to initiate a potentially pivotal Phase 2 program for emraclidine,” said Tony Coles, M.D., chairperson and chief executive officer of Cerevel Therapeutics. “With five data readouts expected next year, a robust set of mid- to late-stage assets, world-class capabilities in drug development, and an ability to execute rapidly to advance our late-stage programs, Cerevel is well-positioned to transform what is possible in neuroscience.”

Pipeline Highlights

Leveraging its deep understanding of neurocircuitry and targeted receptor subtype selectivity, Cerevel is executing on its broad, diverse pipeline of novel neuroscience drug candidates. Below are the latest updates for Cerevel’s lead programs.

Emraclidine: an M4-selective positive allosteric modulator (PAM) in development for schizophrenia as a once-daily medication without the need for titration.

• In June 2022, Cerevel initiated its Phase 2 program in schizophrenia:
  
  
  • Cerevel is conducting two adequately-powered placebo-controlled Phase 2 trials, known as EMPOWER-1 and EMPOWER-2. Data for both trials are expected in the first half of 2024.
  • The primary endpoint is the change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score after six weeks of in-patient treatment.
  • Each trial will enroll 372 individuals living with schizophrenia and experiencing an acute exacerbation of psychotic symptoms who exhibit baseline PANSS total scores from 85 to 120, inclusive.
  • In each trial, patients will be randomized 1:1:1 into one of two emraclidine dose arms or placebo.
    
    
    • The first trial will test emraclidine 10 mg QD, emraclidine 30 mg QD, and placebo.
    • The second trial will test emraclidine 15 mg QD, emraclidine 30 mg QD, and placebo.
  • The trials will enable the full exploration of the therapeutic dose range of emraclidine.
  • In order to accelerate a potentially registrational package for emraclidine in schizophrenia, Cerevel is prioritizing nonclinical and clinical pharmacology studies. Cerevel expects to initiate a 52-week open-label safety extension trial, EMPOWER-3, in the third quarter of 2022. Data from the ongoing eight-week ambulatory blood pressure monitoring trial are expected by the end of 2022.
• To support future development in Alzheimer’s disease psychosis, Cerevel also plans to initiate a Phase 1 multiple ascending dose trial by the end of the year to evaluate the safety, tolerability and pharmacokinetics of emraclidine in elderly healthy volunteers, 65-85 years old.

Darigabat: an α2/3/5-selective GABA_A receptor PAM currently under development for epilepsy and panic disorder.

• Cerevel is conducting the REALIZE trial, a Phase 2 proof-of-concept trial in focal epilepsy. Cerevel expects data in mid-year 2023.
• Based on the positive topline results reported in February 2022 for the Phase 1 trial of darigabat in acute anxiety, Cerevel has selected panic disorder as the second indication for development, in addition to epilepsy, and plans are underway for a Phase 2 proof-of-concept trial in panic disorder, which is the second most common anxiety disorder and can be the most debilitating.  
• Cerevel recently presented darigabat data at the American Society of Clinical Psychopharmacology Annual Meeting, which took place on May 31 – June 3, 2022.
  
  
  • Cerevel presented the positive topline results for its Phase 1 trial of darigabat in acute anxiety.
  • In a separate panel presentation, Cerevel discussed efforts to achieve diversity in clinical trials, an imperative that is a key component of a broader commitment to diversity, equity, and inclusion across all facets of the company.
    

Tavapadon: a D1/D5 partial agonist currently in Phase 3 for the treatment of Parkinson’s disease.

• All three of Cerevel’s Phase 3 trials in early- and late-stage Parkinson’s disease (TEMPO-1, -2, and -3) are ongoing, along with the corresponding open-label extension trial (TEMPO-4).
• Data readouts from the Phase 3 program are expected beginning in the first half of 2023.

CVL-871: a D1/D5 partial agonist in development for treatment of dementia-related apathy.

• In the second quarter of 2021, Cerevel received Fast Track Designation from the FDA for the development of CVL-871 in dementia-related apathy.
• Cerevel is conducting a Phase 2a exploratory trial in dementia-related apathy.
• Data for this trial are anticipated in the first half of 2023.
  

In addition to these lead programs, Cerevel is advancing its early clinical pipeline and discovery programs which include:

• CVL-354, a selective kappa opioid receptor antagonist (KORA) for the treatment of major depressive disorder (MDD) and substance use disorder.
• Selective M4 agonist program for the treatment of psychosis and other related indications.
• CVL-047, a selective PDE4 inhibitor (PDE4D-sparing) for the treatment of MDD and schizophrenia.
  

Financial Results for the Second Quarter 2022

• Cash Position: Cash, cash equivalents and marketable securities as of June 30, 2022, were $531.2 million, inclusive of $37.5M from the tavapadon risk-sharing arrangement received in April 2022. The company’s cash, cash equivalents and marketable securities are expected to continue to support operations into 2024.
  
• R&D Expense: Research and development expense for the second quarter and six months ended June 30, 2022, was $72.5 million and $127.6 million, respectively, compared to $37.3 million and $73.9 million for the prior year periods. Total research and development expense includes equity-based compensation expense of $4.8 million and $8.8 million for the second quarter and six months ended June 30, 2022, respectively. These amounts compare to equity-based compensation expense of $2.1 million and $3.9 million for the prior year periods. The increase in R&D expense is primarily attributable to continued advancement of Cerevel’s clinical programs for tavapadon, emraclidine, and darigabat; investment in preclinical and discovery efforts; and higher personnel and other infrastructure costs as Cerevel expands capabilities to advance its pipeline.
  
• G&A Expense: General and administrative expense for the second quarter and six months ended June 30, 2022, was $20.5 million and $38.0 million, compared to $13.2 million and $27.2 million for the prior year periods. Total general and administrative expense includes equity-based compensation expense of $5.3 million and $9.9 million for the second quarter and six months ended June 30, 2022. These amounts compare to equity-based compensation expense of $3.1 million and $7.4 million for the prior year periods. The increase in G&A expense is primarily due to higher personnel costs as Cerevel continued to grow the organization, the initiation of commercial planning activities, and higher fees and services supporting ongoing business activities.
  

Conference Call Information
Cerevel will host a conference call and webcast today, August 1, 2022 at 8:00 a.m. ET to discuss its second quarter 2022 financial results and pipeline updates. To access the call, please register at this link. Once registered, you will receive the dial-in information and a unique PIN number.

A live webcast of the call, along with supporting slides, will be available on the investors section of Cerevel’s website at investors.cerevel.com. Following the live webcast, an archived version of the call will be available on the website.

About Cerevel Therapeutics
Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling diseases with a targeted approach to neuroscience that combines expertise in neurocircuitry with a focus on receptor selectivity. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including Parkinson’s, epilepsy, schizophrenia, and dementia-related apathy. Headquartered in Cambridge, Mass., Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations, or potential acquisitions. For more information, visit www.cerevel.com.

Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements about the potential attributes and benefits of our product candidates; the format and timing of our product development activities and clinical trials, including the timing, details and objectives of the emraclidine Phase 2 program, nonclinical and clinical pharmacology studies, ambulatory blood pressure monitoring trial, Phase 1 elderly healthy volunteer trial and plans for future development in other indications, including Alzheimer’s disease psychosis, the timing for the darigabat Phase 2 proof-of-concept trial in focal epilepsy, the timing and details of the darigabat Phase 2 proof-of-concept trial in panic disorder, and other statements regarding the design of clinical trials and preclinical studies and the timing of initiation, completion and data readouts for clinical trials; the timing and outcome of regulatory interactions, including whether trials meet the criteria to serve as pivotal; the ability to compete with other companies currently marketing or engaged in the development of treatments for relevant indications; the size and growth potential of the markets for product candidates and ability to serve those markets; the rate and degree of market acceptance of product candidates, if approved; and the sufficiency of our cash, cash equivalents and marketable securities. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties, including, among others: clinical trial results may not be favorable; uncertainties inherent in the product development process (including with respect to the timing of results and whether such results will be predictive of future results); the impact of COVID-19 on the timing, progress and results of ongoing or planned clinical trials; other impacts of COVID-19, including operational disruptions or delays or to our ability to raise additional capital; whether and when, if at all, our product candidates will receive approval from the FDA or other regulatory authorities, and for which, if any, indications; competition from other biotechnology companies; uncertainties regarding intellectual property protection; and other risks identified in our SEC filings, including those under the heading “Risk Factors” in our Quarterly Report on Form 10-Q filed with the SEC on May 10, 2022 and our subsequent SEC filings. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Media Contact:
Anna Robinson
Cerevel Therapeutics
anna.robinson@cerevel.com

Investor Contact:
Matthew Calistri
Cerevel Therapeutics
matthew.calistri@cerevel.com

TABLE 1
CEREVEL THERAPEUTICS HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited, in thousands, except share amounts and per share amounts)
		For the Three Months Ended June 30,								For the Six Months Ended June 30,
			2022				2021				2022				2021
Operating expenses:
Research and development		$	72,539			$	37,294			$	127,562			$	73,855
General and administrative			20,467				13,216				37,974				27,226
Total operating expenses			93,006				50,510				165,536				101,081
Loss from operations			(93,006	)			(50,510	)			(165,536	)			(101,081	)
Interest income, net			667				10				962				25
Other income (expense), net			1,868				(2,739	)			5,809				(3,164	)
Loss before income taxes			(90,471	)			(53,239	)			(158,765	)			(104,220	)
Income tax benefit (provision), net			—				—				—				—
Net loss		$	(90,471	)		$	(53,239	)		$	(158,765	)		$	(104,220	)
Net loss per share, basic and diluted		$	(0.61	)		$	(0.42	)		$	(1.07	)		$	(0.82	)
Weighted-average shares used in calculating net loss per share, basic and diluted			148,295,716				127,482,127				148,141,180				127,354,540

TABLE 2
CEREVEL THERAPEUTICS HOLDINGS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited, in thousands)
		As of
		June 30, 2022			December 31, 2021
ASSETS
Current assets:
Cash and cash equivalents		$	138,218		$	193,018
Marketable securities			392,990			372,670
Prepaid expenses and other current assets			8,933			12,329
Total current assets			540,141			578,017
Marketable securities			—			52,269
Property and equipment, net			29,314			28,449
Operating lease assets			22,573			23,251
Restricted cash			1,867			4,200
Other long-term assets			2,762			2,733
Total assets		$	596,657		$	688,919
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable		$	11,008		$	11,298
Accrued expenses and other current liabilities			43,063			28,803
Operating lease liabilities, current portion			2,672			2,437
Total current liabilities			56,743			42,538
Operating lease liabilities, net of current portion			32,688			34,110
Other long-term liabilities			54,412			33,542
Total stockholders’ equity			452,814			578,729
Total liabilities and stockholders’ equity		$	596,657		$	688,919

TABLE 3
CEREVEL THERAPEUTICS HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited, in thousands)
		For the Six Months Ended June 30,
			2022				2021
Net cash flows used in operating activities		$	(125,304	)		$	(82,026	)
Net cash flows provided by (used in) investing activities			25,752				(8,243	)
Net cash flows provided by financing activities			42,419				33,706
Net decrease in cash, cash equivalents and restricted cash			(57,133	)			(56,563	)
Cash, cash equivalents and restricted cash, beginning of the period			197,218				387,823
Cash, cash equivalents and restricted cash, end of the period		$	140,085			$	331,260
Note:
Cash, cash equivalents and restricted cash balances include restricted cash of $1.9 million and $4.2 million as of June 30, 2022 and June 30, 2021, respectively.

 

 

FAQ

What are the current trials being conducted by Cerevel Therapeutics for emraclidine?

Cerevel is conducting two Phase 2 trials, EMPOWER-1 and EMPOWER-2, for emraclidine in schizophrenia, with data expected in the first half of 2024.

How much cash does Cerevel Therapeutics have as of June 2022?

Cerevel Therapeutics reported cash, cash equivalents, and marketable securities of $531M as of June 30, 2022.

What are the key financial figures for Cerevel Therapeutics for Q2 2022?

Cerevel reported R&D expenses of $72.5M and G&A expenses of $20.5M for Q2 2022.

What is the future outlook for Cerevel's drug development programs?

Cerevel plans to continue advancing its drug candidates, with significant data readouts expected in 2023 and 2024.